Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPYD screening plus PK-guided 5-FU dosing in gastrointestinal cancer
NL-OMON29105Recruiting
- Sponsor
- Isala
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fluorouracil in gastrointestinal cancer (3 cohorts), sponsored by Isala. Primary endpoints: 5-FU clearance at steady state, DPYD genotyping and 1 more. Started Jan 2020; status: recruiting.
02
Drugs
fluorouracil
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NL-OMON29105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29105.